Pixium Vision develops bionic vision systems for patients with severe vision loss. Its lead product, Prima, is a wireless sub-retinal implant system designed for patients with geographic atrophy related to dry-AMD. The company started the PRIMAvera European pivotal study in late 2020, and top-line data are anticipated in early 2023.
In this interview, chief executive officer Lloyd Diamond and chief financial officer Offer Nonhoff discuss how Prima differentiates itself from earlier-generation retinal implants, and provide details on the ongoing PRIMAvera study as well as the planned commercial strategy for the US and key European markets. They also review the company’s financial position and objectives, and comment on longer-term development opportunities. Finally, the company’s executives highlight some of the key catalysts and milestones expected over the next year.